Logo image of VIR

VIR BIOTECHNOLOGY INC (VIR) Stock Fundamental Analysis

NASDAQ:VIR - Nasdaq - US92764N1028 - Common Stock - Currency: USD

5.24  +0.02 (+0.38%)

After market: 5.24 0 (0%)

Fundamental Rating

4

VIR gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 557 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for VIR as it has an excellent financial health rating, but there are worries on the profitability. While showing a medium growth rate, VIR is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year VIR has reported negative net income.
In the past year VIR has reported a negative cash flow from operations.
In multiple years VIR reported negative net income over the last 5 years.
VIR had negative operating cash flow in 4 of the past 5 years.
VIR Yearly Net Income VS EBIT VS OCF VS FCFVIR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M 1B 1.5B

1.2 Ratios

VIR has a Return On Assets of -44.17%. This is comparable to the rest of the industry: VIR outperforms 53.86% of its industry peers.
VIR has a better Return On Equity (-55.34%) than 62.30% of its industry peers.
Industry RankSector Rank
ROA -44.17%
ROE -55.34%
ROIC N/A
ROA(3y)-16.99%
ROA(5y)-11.28%
ROE(3y)-19.74%
ROE(5y)-12.79%
ROIC(3y)N/A
ROIC(5y)N/A
VIR Yearly ROA, ROE, ROICVIR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 -40 -60 -80

1.3 Margins

VIR's Gross Margin of 96.23% is amongst the best of the industry. VIR outperforms 96.05% of its industry peers.
In the last couple of years the Gross Margin of VIR has grown nicely.
The Profit Margin and Operating Margin are not available for VIR so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 96.23%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.7%
GM growth 5YN/A
VIR Yearly Profit, Operating, Gross MarginsVIR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K

More info and screens

7

2. Health

2.1 Basic Checks

VIR does not have a ROIC to compare to the WACC, probably because it is not profitable.
VIR has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, VIR has more shares outstanding
VIR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
VIR Yearly Shares OutstandingVIR Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
VIR Yearly Total Debt VS Total AssetsVIR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B 2.5B

2.2 Solvency

VIR has an Altman-Z score of -0.09. This is a bad value and indicates that VIR is not financially healthy and even has some risk of bankruptcy.
With a decent Altman-Z score value of -0.09, VIR is doing good in the industry, outperforming 62.48% of the companies in the same industry.
There is no outstanding debt for VIR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -0.09
ROIC/WACCN/A
WACC9.05%
VIR Yearly LT Debt VS Equity VS FCFVIR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M 1B 1.5B 2B

2.3 Liquidity

VIR has a Current Ratio of 6.79. This indicates that VIR is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of VIR (6.79) is better than 65.35% of its industry peers.
VIR has a Quick Ratio of 6.79. This indicates that VIR is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 6.79, VIR is in the better half of the industry, outperforming 65.71% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 6.79
Quick Ratio 6.79
VIR Yearly Current Assets VS Current LiabilitesVIR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B 2.5B

More info and screens

5

3. Growth

3.1 Past

The earnings per share for VIR have decreased by -5.24% in the last year.
VIR shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -73.78%.
The Revenue has been growing by 55.74% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-5.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-83.33%
Revenue 1Y (TTM)-73.78%
Revenue growth 3Y-59.24%
Revenue growth 5Y55.74%
Sales Q2Q%-94.62%

3.2 Future

The Earnings Per Share is expected to grow by 7.97% on average over the next years.
The Revenue is expected to grow by 21.17% on average over the next years. This is a very strong growth
EPS Next Y11.15%
EPS Next 2Y6.88%
EPS Next 3Y6.69%
EPS Next 5Y7.97%
Revenue Next Year-76.15%
Revenue Next 2Y-51.36%
Revenue Next 3Y-29.72%
Revenue Next 5Y21.17%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
VIR Yearly Revenue VS EstimatesVIR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 500M 1B 1.5B
VIR Yearly EPS VS EstimatesVIR Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 2 -2 4 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for VIR. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VIR. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VIR Price Earnings VS Forward Price EarningsVIR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VIR Per share dataVIR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y6.88%
EPS Next 3Y6.69%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for VIR!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VIR BIOTECHNOLOGY INC

NASDAQ:VIR (6/16/2025, 8:15:07 PM)

After market: 5.24 0 (0%)

5.24

+0.02 (+0.38%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-07 2025-05-07/amc
Earnings (Next)07-30 2025-07-30/amc
Inst Owners65.14%
Inst Owner Change6.58%
Ins Owners1.19%
Ins Owner Change-0.1%
Market Cap724.38M
Analysts78.46
Price Target18.8 (258.78%)
Short Float %13.09%
Short Ratio8.68
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)4.75%
Min EPS beat(2)-4.26%
Max EPS beat(2)13.76%
EPS beat(4)1
Avg EPS beat(4)-12.51%
Min EPS beat(4)-46.72%
Max EPS beat(4)13.76%
EPS beat(8)3
Avg EPS beat(8)0.1%
EPS beat(12)4
Avg EPS beat(12)-4.47%
EPS beat(16)8
Avg EPS beat(16)226.37%
Revenue beat(2)1
Avg Revenue beat(2)-7.27%
Min Revenue beat(2)-65.06%
Max Revenue beat(2)50.52%
Revenue beat(4)1
Avg Revenue beat(4)-32.79%
Min Revenue beat(4)-65.06%
Max Revenue beat(4)50.52%
Revenue beat(8)3
Avg Revenue beat(8)15.28%
Revenue beat(12)5
Avg Revenue beat(12)7.88%
Revenue beat(16)8
Avg Revenue beat(16)15.69%
PT rev (1m)-45.11%
PT rev (3m)-46.69%
EPS NQ rev (1m)6.65%
EPS NQ rev (3m)11.02%
EPS NY rev (1m)0%
EPS NY rev (3m)9.41%
Revenue NQ rev (1m)-3.87%
Revenue NQ rev (3m)-64.9%
Revenue NY rev (1m)-5.67%
Revenue NY rev (3m)-39.43%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 34.72
P/FCF N/A
P/OCF N/A
P/B 0.69
P/tB 0.71
EV/EBITDA N/A
EPS(TTM)-4.22
EYN/A
EPS(NY)-3.28
Fwd EYN/A
FCF(TTM)-3.05
FCFYN/A
OCF(TTM)-3
OCFYN/A
SpS0.15
BVpS7.55
TBVpS7.37
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -44.17%
ROE -55.34%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 96.23%
FCFM N/A
ROA(3y)-16.99%
ROA(5y)-11.28%
ROE(3y)-19.74%
ROE(5y)-12.79%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.7%
GM growth 5YN/A
F-Score2
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 54.68%
Cap/Sales 33.83%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.79
Quick Ratio 6.79
Altman-Z -0.09
F-Score2
WACC9.05%
ROIC/WACCN/A
Cap/Depr(3y)387.02%
Cap/Depr(5y)331.46%
Cap/Sales(3y)13.03%
Cap/Sales(5y)9.92%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-5.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-83.33%
EPS Next Y11.15%
EPS Next 2Y6.88%
EPS Next 3Y6.69%
EPS Next 5Y7.97%
Revenue 1Y (TTM)-73.78%
Revenue growth 3Y-59.24%
Revenue growth 5Y55.74%
Sales Q2Q%-94.62%
Revenue Next Year-76.15%
Revenue Next 2Y-51.36%
Revenue Next 3Y-29.72%
Revenue Next 5Y21.17%
EBIT growth 1Y1.52%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year13.52%
EBIT Next 3Y4.52%
EBIT Next 5Y8.53%
FCF growth 1Y-145.47%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-142.04%
OCF growth 3YN/A
OCF growth 5YN/A